Vyriad, a gene therapy company based in Rochester, has raised $85 million to support its new VV-169 cancer treatment which ...

In this week's "It's Debatable" segment, Rick Rosen and Charles Moster debate on the question: Should ethical/legal restrictions on human testing be lifted to expedite the development of new ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

For the first time, a federal health agency’s cervical cancer screening guidance includes an option for women to collect ...